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Abstract
Aims: Nuclear factor (erythroid-derived 2)-like 2 (NRF2) is a master regulator of oxidant and xenobiotic
metabolism, but it is unknown how it is regulated to provide basal expression of this defense system. Here, we
studied the putative connection between NRF2 and the canonical WNT pathway, which modulates hepatocyte
metabolism. Results: WNT-3A increased the levels of NRF2 and its transcriptional signature in mouse he-
patocytes and HEK293T cells. The use of short interfering RNAs in hepatocytes and mouse embryonic fi-
broblasts which are deficient in the redox sensor Kelch-like ECH-associated protein 1 (KEAP1) indicated that
WNT-3A activates NRF2 in a b-Catenin- and KEAP1-independent manner. WNT-3A stabilized NRF2 by
preventing its GSK-3-dependent phosphorylation and subsequent SCF/b-TrCP-dependent ubiquitination and
proteasomal degradation. Axin1 and NRF2 were physically associated in a protein complex that was regulated
by WNT-3A, involving the central region of Axin1 and the Neh4/Neh5 domains of NRF2. Axin1 knockdown
increased NRF2 protein levels, while Axin1 stabilization with Tankyrase inhibitors blocked WNT/NRF2 sig-
naling. The relevance of this novel pathway was assessed in mice with a conditional deletion of Axin1 in the
liver, which showed upregulation of the NRF2 signature in hepatocytes and disruption of liver zonation of
antioxidant metabolism. Innovation: NRF2 takes part in a protein complex with Axin1 that is regulated by the
canonical WNT pathway. This new WNT-NRF2 axis controls the antioxidant metabolism of hepatocytes.
Conclusion: These results uncover the participation of NRF2 in a WNT-regulated signalosome that participates
in basal maintenance of hepatic antioxidant metabolism. Antioxid. Redox Signal. 22, 555–571.
Introduction
Transcription factor nuclear factor (erythroid-derived2)-like 2 (NRF2, also known as NFE2L2) controls the
expression of about 1% of human genes, which participate
in biotransformation reactions, redox status, energetic me-
tabolism, and proteostasis (1, 15, 18, 24, 32, 55). These genes
possess a cis-acting regulatory sequence termed antioxidant
response element (ARE) (20, 53) and include, among many
others, the ones used in this study in connection with oxidant
metabolism (1, 15, 16, 55). Given the relevance of the liver
in energetic metabolism and biotransformation reactions,
NRF2 has been extensively studied in metabolic adaptation
of hepatocytes (25, 42, 57). NRF2 also participates in liver
regeneration (3, 17, 27, 52) and promotes compensatory liver
hypertrophy after portal vein branch ligation in mice (43).
NRF2 is controlled by a complex array of transcrip-
tional regulators and post-translational modifications that
ensure proper transcriptional activity, under basal conditions
and under adaptation to environmental changes (15). Most
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studies have focused on the role of the eletrophile and redox
sensor Kelch-like ECH-associated protein 1 (KEAP1) to
adjust NRF2 protein levels to metabolic demands. KEAP1
interacts with two regions of NRF2 (amino-acid sequences
DLG and ETGE) located at the Neh2N-terminal domain to
direct ubiquitination by the Cullin-3/Rbx1 complex and
proteasome degradation of NRF2 (8, 26, 51, 56). On ele-
trophile modification or oxidation of KEAP1, the interaction
with NRF2 is disrupted. Then, NRF2 escapes degradation,
enters the nucleus, and targets ARE genes to increase the
capacity of antioxidant and biotransformation reactions (31,
48). While the KEAP1 regulation elegantly explains how
NRF2 levels adjust to metabolic demands, it does not clarify
the role of NRF2 under basal homeostatic conditions or when
KEAP1 activity is limiting (see Discussion). Moreover, het-
erozygous deletion in the Keap1 gene has different effects on
the NRF2 transcriptional signatures of the forestomach, in-
testine, and liver (32), further supporting the existence of
other layers of tissue-specific NRF2 regulation.
We have previously reported that glycogen synthase
kinase-3 (GSK-3) phosphorylates NRF2 in the Neh6 domain
(amino-acid sequence DSGISL) to create a recognition site
for the E3 ligase adapter SCF/b-TrCP (38, 39). This, in turn,
leads to ubiquitin-proteasome degradation of NRF2 through a
Cullin-1/Rbx1 complex. The two prototypic mechanisms of
regulation of GSK-3/b-TrCP comprise the insulin and WNT
pathways, where GSK-3 is regulated via phosphorylation or
protein complex formation, respectively, but the participa-
tion of these pathways in NRF2 regulation has been hardly
addressed.
Regarding insulin, it has been suggested that the protein
tyrosine phosphatase 1B modulates GSK3b/NRF2 and
Insulin-like Growth Factor-1 Receptor signaling pathways in
a model of acetaminophen-induced hepatotoxicity (33). Two
recent studies showed that loss of a downstream regulator of
insulin signaling, the tumor suppressor phosphatase and
tensin homolog (PTEN), results in inhibition of GSK-3 and
subsequent induction of NRF2, leading to enhanced cho-
langiocyte expansion in mice (46) and endometrial carcino-
genesis in humans (41).
The experimental evidence connecting NRF2 and WNT
signaling is even scarcer despite the fact that WNT is in-
strumental in acquisition and maintenance of the metabolic
signatures of hepatocytes (2, 21, 34, 49). In this study, we
have analyzed this connection and its relevance in antioxi-
dant metabolism of hepatocytes taking b-Catenin as a qual-
ified control. In the absence of canonical WNT signaling,
b-Catenin is recruited to a multi-protein complex composed
by the scaffold proteins Axin1 and adenomatous polyposis
coli and the kinases casein kinase 1 and GSK-3b (45). This
protein complex phosphorylates b-Catenin on conserved
N-terminal Ser and Thr residues, thereby marking it for
recognition by SCF/b-TrCP and Cullin-1/Rbx1-mediated
ubiquitination and proteasomal degradation. WNT binding to
its receptors Frizzled and LRP5/6 at the cell surface results
in the disassembly of b-Catenin from the Axin1-GSK-3b
complex, leading to accumulation of dephosphorylated b-
Catenin, nuclear import, binding to T-cell factor/lymphoid
enhancer factor (TCF/LEF), and upregulation of downstream
genes (11).
Here, we report that NRF2 participates in the formation of
a protein complex with Axin1/GSK-3/b-TrCP that is dis-
rupted byWNT-3A, a prototypic canonical WNT ligand, and
leads to upregulation of the NRF2 transcriptional signature.
This new signaling axis is KEAP1 independent and, there-
fore, controls antioxidant metabolism of hepatocytes under
basal eletrophile pressure.
Innovation
We identify a completely novel regulation of nuclear
factor (erythroid-derived 2)-like 2 (NRF2) by the canon-
ical WNT signaling pathway that is redox independent
and not connected with b-Catenin. At the mechanistic
level, we show for the first time that NRF2 associates with
Axin1 in a WNT-3A-regulated signalosome. Here, NRF2
is phosphorylated by GSK-3 and targeted for ubiquitin/
proteasome degradation by b-TrCP. At the functional le-
vel, the relevance of this new pathway is demonstrated in
mice with a conditional deletion of Axin1 in the liver.
Depletion of Axin1 in these mice results in upregulation
of the NRF2-dependent antioxidant metabolism most
prominently in hepatocytes of the perivenous zone.
FIG. 1. WNT-3A induces the NRF2 transcriptional signature. (A–E) mRNA levels of Axin2, Gs, Hmox1, Nqo1, and
Gpx1 normalized by Actb (coding b-Actin) levels, after stimulation of mouse hepatocytes with WNT-3A-CM. (F) Im-
munoblots from mouse hepatocytes stimulated with WNT-3A-CM showing NRF2, b-Catenin, HO-1, and GS levels.
GADPH levels were used as a loading control. (G) Densitometric quantification of protein levels from representative blots
of (F). (H–K) Mouse hepatocytes were transfected with specific siRNAs to knock down Nfe2l2 (coding NRF2) and
stimulated with WNT-3A-CM for 6 h. Messenger RNA levels of Nfe2l2 (H), Hmox1 (I), Nqo1 ( J), and Axin2 (K) were
normalized by Actb levels. For (A–K), values are mean – SEM (n = 3). Statistical analysis was performed with one-way
ANOVA followed by Newman–Keuls multiple-comparison test. *p< 0.05, **p < 0.01, and ***p< 0.001 versus t= 0 or
control groups. (L, M) HEK293T cells were co-transfected with ARE-LUC (L) or TOPFlash (M) and pTK-Renilla for
normalization, plus NRF2DETGE-V5 or b-Catenin expression vectors, as indicated. Then, cells were treated with Control- or
WNT-3A-CM (16 h). Luciferase activity was measured after 24 h from transfection. Values are mean – SEM (n = 3).
*p < 0.05 and **p < 0.01 versus control CM, according to a Student’s t-test. (N) HEK293T cells were transfected with
NRF2DETGE-V5 or b-Catenin as indicated, plus HA-GSK-3bD9 and Flag-b-TrCP. After 24 h, cells were treated with MG132
(40 lM, 3 h). One-fifth of protein lysate was used to control for protein expression as shown in the upper panels (input). The
rest of the protein lysates were immunoprecipitated with anti-V5 or anti-b-Catenin or G protein as a control, and im-
munoblotted as indicated in the lower panels (pull down). Filled arrowheads point to HA-GSK-3D9, and Flag-b-TrCP.
Empty arrowheads point to the heavy chains of the anti-V5 and anti-b-Catenin antibodies. ANOVA, analysis of variance;
ARE, antioxidant response element; CM, conditioned medium; HEK, human embryonic kidney; HO-1, heme oxygenase-1;
GSK-3, glycogen synthase kinase-3; NRF2, nuclear factor (erythroid-derived 2)-like 2; siRNA, short interfering RNA.
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Results
The canonical WNT pathway regulates
the NRF2/ARE axis
We first analyzed the regulation of NRF2 by WNT-3A.
In isolated mouse hepatocytes (Fig. 1A–E), WNT-3A-
conditioned medium (CM) (see Materials and Methods) in-
duced a time-dependent increase in the messenger RNA
levels of two well-established WNT/b-Catenin targets, Axin2
and Gs (coding glutamine synthetase [GS]), as expected, but,
very interestingly, there was a parallel upregulation of genes
traditionally considered targets of NRF2, such as Hmox1 (cod-
ing heme oxygenase-1 [HO-1]), Nqo1 (NAD(P)H:quinone
oxidoreductase 1), and Gpx1 (glutathione peroxidase 1). At
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FIG. 2. WNT-3A increases NRF2 protein levels in a KEAP1-independent manner. (A) Cytosolic and nuclear extracts
from Keap1 - / - and Keap1 + / + MEFs treated with control- or WNT-3A-CM for 4 h were immunoblotted with the indicated
antibodies. (B) Whole-protein lysates were immunoblotted with the specified antibodies. The filled arrowhead points to the
band corresponding to GCLM. (C) Densitometric quantification of protein levels from representative blots such as those in
(B). Values are mean – SEM (n= 3). **p < 0.01 and ***p < 0.001 versus Keap1 + /+ MEFs treated with control medium,
according to a Student’s t-test. (D) Keap1+ / + or Keap1 - / - MEFs were transiently co-transfected with ARE-LUC or
TOPFlash reporters, pTK-Renilla, as control, and expression vector for WNT-3A-HA or empty vector. Luciferase activity
was measured after 48 h from transfection. Values are mean – SEM (n = 3). **p < 0.01 and ***p< 0.001 versus MEFs
transfected with empty vector, according to a Student’s t-test. KEAP1, Kelch-like ECH-associated protein 1; MEFs, mouse
embryonic fibroblasts.
FIG. 3. WNT-3A increases NRF2 protein levels in a GSK-3/b-TrCP-dependent manner. (A) HEK293T cells were
transfected with NRF2-V5. After 24 h, they were further transfected with siRNAs for GSK-3a, GSK-3b, or both or with
a control scrambled siRNA. Cells were lysed at 24 h after siRNA transfection. Whole-protein lysates were im-
munoblotted with specific antibodies as indicated in the panels. (B–E) Mouse hepatocytes were transfected with specific
siRNAs to knock down b-TrCP1 (Btrc) and b-TrCP2 (Fbxm11). (B, C) mRNA levels of b-TrCP1 and b-TrCP2 after
siRNA knockdown. (D, E) mRNA levels of HO-1 and NQO1, respectively, in hepatocytes with specific knockdown of
the indicated genes after stimulation with control- or WNT-3A-CM for 6 h. Messenger RNA levels were determined by
quantitative real time PCR (qRT-PCR) normalized with b-Actin. Values are mean – SEM (n= 3). Statistical analysis was
performed with one-way ANOVA followed by Newman–Keuls multiple-comparison test. *p < 0.05, **p < 0.01, and
***p< 0.001 versus hepatocytes transfected with scrambled siRNA and treated with control-CM. (F) HEK293T cells
were co-transfected with NRF2DETGE-V5 and b-TrCPDFbox-HA. After 24 h, cells were treated with control- or WNT-3A-
CM for 3 h. Whole-protein lysates were immunoblotted with specific antibodies as indicated in the panels. (G)
HEK293T cells were co-transfected with the NRF2DETGE-V5 or NRF2DETGE 6S6A-V5 and His-tagged Ubiquitin. Twenty-
four hours after transfection, cells were treated with MG132 for 3 h. Ubiquitinated proteins were isolated in a nickel
column, resolved in SDS-PAGE, and immunoblotted with anti-V5 antibody as indicated. Whole-cell lysate (input) and
affinity-purified His-tagged fractions (His-Pull down) were blotted with anti-V5 antibody. Filled and empty arrowheads
point to the positions of NRF2DETGE-V5 and NRF2DETGE 6S6A-V5, respectively. The bracket indicates the mobility of
polyubiquitinated forms of NRF2-V5 (NRF2-Ub).
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the protein level, WNT-3A not only increased b-Catenin and
GS, but it also led to a comparable increase in NRF2 and
HO-1 (Fig. 1F, G). Recombinant WNT-3A also induced a
dose-dependent and time-dependent increase in b-Catenin,
NRF2, and HO-1 protein levels (Supplementary Fig. S1;
Supplementary Data are available online at www.liebertpub
.com/ars). These findings correlated with increased NRF2
levels, translocation to the nuclear fraction (Supplementary
Fig. S2A), and increased transcriptional activity as deter-
mined with an ARE-driven luciferase reporter construct,
ARE-LUC, containing three AREs from the mouse Hmox1
promoter (Supplementary Fig. S2B, C). Considering that in
later experiments we would need to use heterologous ex-
pression of NRF2 mutants and WNT signaling proteins, we
further validated these observations in human embryonic
kidney (HEK) 293T cells that have an intact WNT-3A sig-
naling pathway (29), and we obtained similar outcomes
(Supplementary Fig. S3).
To formally demonstrate a role of NRF2 in induction of
antioxidant enzymes by WNT-3A, we knocked down Nrf2
A WNT-3A/NRF2 AXIS REGULATES ANTIOXIDANT METABOLISM 559
(Nfe2l2) expression in mouse hepatocytes with interfering
RNA (Fig. 1H–K). Knockdown of Nrf2 rendered hepatocytes
completely unresponsive to WNT-3A-dependent induction
of Hmox1 and Nqo1, while Axin2 expression was unaffected.
Altogether, these results demonstrate that theWNT canonical
pathway regulates the NRF2/ARE axis.
To further determine whether there might be a functional
interference between NRF2 and b-Catenin, we used their
respective luciferase reporters ARE-LUC and TOPFlash.
HEK293T cells were co-transfected with either of these re-
porters plus pTK-Renilla as control and different amounts
of expression vectors for NRF2DETGE-V5 or b-Catenin.
NRF2DETGE-V5 is a stable mutant version of NRF2 with an
extended stability, because it lacks the high-affinity bind-
ing site for KEAP1 (30, 38, 39). Then, cells were treated with
WNT-3A for 16 h. As shown in Figure 1L and M, over-
expression of NRF2 but not b-Catenin induced the ARE re-
porter andWNT-3A led to a similar increase of ARE activity.
On the other hand, over-expression of b-Catenin but not
NRF2 induced the TOPFlash reporter and WNT-3A led to
a similar induction. We also analyzed whether NRF2 and
b-Catenin might be a part of a common protein complex.
As shown in Figure 1N, immunoprecipitation of either
NRF2 or b-Catenin did not pull down the other. As a
positive control, we observed that two well-known NRF2
and b-Catenin interacting proteins, GSK-3b and b-TrCP, co-
immunoprecipitated with NRF2 or with b-Catenin. There-
fore, our results suggest that these two transcription factors
are not associated in a common protein complex and that
WNT-3A targets them independently.
WNT regulates NRF2 through a KEAP1-independent
but GSK-3/b-TrCP-dependent mechanism
Considering that KEAP1 is the redox-dependent control-
ler of NRF2 stability, we studied whether this E3 ligase
adapter might participate in WNT signaling to NRF2 by
using mouse embryonic fibroblasts (MEFs) derived from
KEAP1-deficient (Keap1 - / - ) and wild-type (Keap1 + /+ )
mice as a control. WNT-3A (4 h) increased the protein levels
of NRF2 in wild-type MEFs in both the cytosolic and nuclear
fractions in parallel to the increase in b-Catenin used as a
control (Fig. 2A). As previously reported, the baseline NRF2
protein levels in Keap1 - / - MEFs were modestly higher
than in Keap1 + / + MEFs due to the disruption of KEAP1-
mediated degradation of NRF2 (38). However, more relevant,
WNT-3A also increased NRF2 levels in Keap1- /- MEFs.
Moreover, on WNT-3A stimulation, we found an induction of
approximately two-fold in the NRF2-regulated enzymes
HO-1, NQO1, GCLC, and GCLM in both cell lines (Fig. 2B,
C). As an alternative approach, we further explored the effect
of WNT-3A on the NRF2 transcriptional activity in Keap1+ /+
and Keap1- /- MEFs transfected with the NRF2 luciferase
reporter ARE-LUC/pTK-Renilla and the b-Catenin reporter
TOP/FOPFlash as control (Fig. 2D). Regardless of the geno-
type, WNT-3A led to a similar increase in ARE-LUC activity.
These results further confirm that WNT-3A stabilizes NRF2
protein levels by a KEAP1-independent mechanism.
SinceGSK-3plays a key role in theWNTsignalingpathway,
we studied whether GSK-3a or GSK-3b might be involved in
the upregulation of NRF2 mediated by WNT-3A. For this
purpose, we knocked down each GSK-3 isoform with short
interfering RNAs (siRNAs). HEK293T cells were transfected
with an expression vector for NRF2-V5 and then with siRNA
against GSK-3a, GSK-3b, or both isoforms (Fig. 3A). Partial
knockdown of either protein isoform (about 50%–60% for
GSK-3a, and 60%–70% for GSK-3b) was enough to increase
NRF2 protein levels, and this effect was maximal when both
isoforms were knocked down together. WNT-3A also in-
creased NRF2 protein levels and, in this case, knockdown of
GSK-3a, b, or both did not lead to a further effect. A similar
effect was observed for b-Catenin, used as a control.
We have previously reported that the E3 ligase adapter SCF/
b-TrCP targets NRF2 for proteasome degradation when it had
been previously phosphorylated by GSK-3. Therefore, to test
the involvement of b-TrCP in the context ofWNT signaling to
NRF2, we knocked down b-TrCP1 and b-TrCP2 with siRNA
in mouse hepatocytes (Fig. 3B–E). Reduction of b-TrCP1/2
levels led to a statistically significant increase in the basal
mRNA levels of HO-1 and NQO1, which were close to satu-
ration under WNT-3A induction. This outcome is consistent
with a role of this E3 ligase as a negative regulator of NRF2 (7,
38, 39). As an alternative approach, we expressed a dominant-
negative mutant (b-TrCPDFbox), which lacks the Fbox motif
and cannot form functional complexes with Cullin-1/Rbx1 but
competes with endogenous b-TrCP for binding to its substrates
(54). To avoid a potential interference with KEAP1, we used
the KEAP1-insensitive NRF2 mutant (NRF2DETGE-V5).
HEK293T cells were co-transfected with NRF2DETGE-V5 and
b-TrCPDFbox-HA, and after 24 h were treated with WNT-3A-
or control-CM for 3 h (Fig. 3F). When NRF2 stabilization
was achieved by the presence of b-TrCPDFbox, WNT-3A did
not promote an additional increase in NRF2, indicating that
the inactivation of b-TrCP is involved in the stabilization of
NRF2mediated byWNT-3A. Similar results were found with
stabilization of b-Catenin, carried as a control.
Further evidence for the role of WNT-3A in the GSK-3/
b-TrCP-mediated regulation of NRF2 was obtained by
analyzing the pattern of NRF2 ubiquitination (Fig. 3G).
HEK293T cells were co-transfected with plasmids expres-
sing NRF2DETGE-V5, His-Ubiquitin, and either the control
vector or an expression plasmid for HA-tagged WNT-3A.
Since NRF2DETGE-V5 is not targeted by KEAP1, ubiquiti-
nation of this protein rests on other E3 ligase adaptors such as
b-TrCP (7, 38, 39). As a control for the GSK-3-independent
NRF2-ubiquitination, we also examined the levels of ubiqui-
tinated NRF2DETGE 6S/6A-V5, a mutant that is insensitive to
both KEAP1 and GSK-3/b-TrCP-mediated degradation path-
ways (38, 39). WNT-3A led to a significant reduction in the
ubiquitination of NRF2DETGE to levels comparable to those of
NRF2DETGE 6S/6A, indicating that WNT-3A is blocking NRF2
degradation through the inhibition of GSK-3/b-TrCP pathway.
We could still detect residual polyubiquitinated NRF2 in the
presence of WNT-3A and in NRF2DETGE 6S/6A, indicating the
existence of other possible proteasome degradation motifs
apart from those involving GSK-3 pathways (7). Taken to-
gether, these findings demonstrate that the WNT canonical
pathway regulates NRF2 through a mechanism which implies
the inhibition of GSK-3/b-TrCP axis.
Axin1 is involved in the regulation of NRF2
Axin1 is an essential element of theWNT signalosome that
scaffolds specific kinases and substrates together (36). To
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study the possible connection between NRF2 and Axin1, first
we knocked down the expression of Axin1 in Keap1 - /-
MEFs. In line with the previous data, siRNA-mediated de-
pletion of Axin1 resulted in high NRF2 and b-Catenin protein
levels (Fig. 4A, B). Then, we used two recently characterized
small-moleculeWNT inhibitors named XAV939 and IWR-1,
which inhibit Tankyrase-dependent degradation of Axin1
(6, 19). HEK293T cells were treated for 16 h with vehicle
(DMSO), XAV939 (10 lM), or IWR-1 (20 lM) and then with
WNT-3A-CM for the time points indicated in Figure 4C–E.
As expected, Axin1 protein levels were stabilized in
HEK293T cells treated with XAV939 or IWR-1. Interestingly,
both WNT inhibitors blocked NRF2- as well as b-Catenin-
induction, in response to WNT-3A. Similar results were ob-
tained in mouse hepatocytes (Supplementary Fig. S4). Overall,
these data show that genetic inactivation or pharmacologic
stabilization of Axin1 inverselymodulates NRF2 protein levels.
These results suggested that NRF2 might be a part of a
protein complex with Axin1 as is the case for b-Catenin. To
determinewhether endogenousNRF2 andAxin1 proteins could
be physically associated, we used a co-immunoprecipitation
assay in mouse hepatocytes. Cells were treated with MG132
(40lM) for 3 h to prevent NRF2 and b-Catenin degradation and
maintain the protein complexes. Both NRF2 and b-Catenin
associated with Axin1 in the same samples (data not shown)
and, very importantly, WNT-3A disrupted the Axin1/NRF2
association (Fig. 5A).
Molecular details of Axin1 and NRF2 association were
further explored in HEK293T cells. In Figure 5B, KEAP1-
insensitive NRF2DETGE-V5 or b-Catenin, as control, were
co-transfected with myc-Axin1, HA-GSK-3bD9, and b-TrCP.
Then, cells were maintained in low-serum medium for 16h
and finally treated with WNT-3A. Cellular lysates were im-
munoprecipitated with anti-V5 for NRF2 or anti-b-Catenin. In
line with the results obtained in hepatocytes, we found that
Axin1 interacts not only with NRF2 and b-Catenin but also with
GSK-3b and b-TrCP. Moreover, these interactions were re-
duced byWNT-3A, suggesting that this factor disassembles the
protein complex. Taken together, these data indicate that NRF2
is bound to Axin1 and released from it onWNT-3A stimulation.
Characterization of the regions of interaction
between NRF2 and Axin1
We generated four myc-tagged amino-terminal dele-
tion mutants of mouse Axin1 by consecutive exon deletion
FIG. 4. Genetic and chemical manipulation of Axin1 alters both WNT/NRF2 and WNT/b-Catenin signaling. (A)
Messenger RNA levels of Axin1 normalized by Actb in Keap1- / - MEFs transfected with control scrambled or Axin1
siRNAs. Statistical analysis was performed with a Student’s t-test. ***p < 0.001 versus scramble siRNA. (B) Whole-protein
lysates of these MEFs were immunoblotted as indicated. (C) HEK293T cells were treated with the WNT inhibitors XAV939
(10 lM) or IWR-1 (20lM) or vehicle (DMSO) for 16 h, and then stimulated with WNT-3A-CM according to the indicated
time points. Whole-protein lysates were immunoblotted with specific antibodies as indicated in the panels. (D, E) Densi-
tometric quantification of NRF2 and b-Catenin protein levels from representative blots of (C). Statistical analysis was
performed with one-way ANOVA followed by Newman–Keuls multiple-comparison test. **p< 0.01 versus t = 0.
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from the 3¢-end (Fig. 5C). Then, HEK293T cells were co-
transfected with these Axin1 deletion mutants and either
b-Catenin, as control (Fig. 5E), or NRF2DETGE-V5 (Fig. 5F).
Co-immunoprecipitation experiments revealed that the
Axin1/b-Catenin complex is formed only when exon 6 of
Axin1 is present. Regarding NRF2DETGE-V5, when cellular
lysates were pulled down with anti-V5 antibody, we detected
that, similar to b-Catenin, loss of exon 6 resulted in a dra-
matic reduction of the amount of Axin1 bound to NRF2.
In additional experiments, we determined the region of
NRF2 required for Axin1 binding by the use of fusion pro-
teins carrying enhanced yellow fluorescent protein (EYFP)
and progressive N-terminal truncations of NRF2, as sche-
matically indicated in Figure 5D. The EYFP-NRF2 chimera
D1 lacks the Neh2 domain required for binding to KEAP1; it
retains the ability to bind Axin1, and this interaction is lost in
the presence ofWNT-3A (Supplementary Fig. S5). As shown
in Figure 5G, immunoprecipitation of NRF2 chimeras re-
vealed that the region comprising the Neh4 and Neh5 domains
(i.e., EYFP-NRF2D2-V5) is required for binding to Axin1.
Conditional disruption of Axin1 in the liver results
in increased NRF2 transcriptional activity
We analyzed NRF2 function in the liver of transgenic mice
with a conditional liver-specific depletion ofAxin1 (Axin1- /- )
(see Materials and Methods). As shown in Figure 6A and B,
these mice showed a dramatic depletion of Axin1. Further-
more, in agreement with (10), total b-Catenin and GS protein
levels were not substantially altered. Regarding NRF2, the
depletion of Axin1 resulted in upregulation of the NRF2
signature as determined by increased NRF2 protein levels
and a two- to four-fold induction of six enzymes regulated
by this transcription factor: HO-1, NQO1, GCLC, GCLM,
ME1 (malic enzyme 1), and G6PDH (glucose 6 phosphate
dehydrogenase). In addition, quantitative real time PCR
(qRT-PCR) was used to analyze messenger RNA levels of
well-known NRF2 andWNT-specific targets. Levels of Axin1
mRNA were strongly reduced, while there was a modest in-
crease in Axin2 and Myc gene expression and no change in
CyclinD1 andGs (Fig. 6C). Thismodest increase inb-Catenin-
regulated genes is comparable to that reported in the initial
characterization of these mice (10) and suggests a compensa-
tory mechanism, maybe mediated in part through Axin2 up-
regulation. However, more importantly for our study, with the
exception of Gclc, mRNA levels of the NRF2-targeted en-
zymesHmox1, Nqo1, Gclm,Gpx,Gsta2,Gstm3, andMe1were
increased in Axin1- /- livers (Fig. 6D). These results demon-
strate that the basal NRF2 transcriptional signature is inversely
dependent on the availability of Axin1 in the liver.
We sought to determine whether Axin1 - /- mice show
alterations in the phenotypic distribution of enzymes regu-
lated transcriptionally by NRF2. Five-micrometers-thick
sections of paraffin-embedded livers were first stained with
an anti-NRF2 antibody. Figure 7A shows low and high
magnification of NRF2 staining in representative perivenous
zones, and Figure 7B shows a negative control in the liver of
Nrf2 - / - mice. We found that NRF2 was cytosolic and nu-
clear in Axin1+ / + mice. In Axin1 - /- mice, NRF2 staining
was increased, suggesting not only in agreement with Figure
6 that it was upregulated in the absence of Axin1, but also we
counted more hepatocytes with a nuclear accumulation of
NRF2 (Fig. 7C). GS distribution was not altered in Axin1 - /-
livers, as expected (10), indicating that other elements of the
WNT pathway may be responsible for regulation of ammonia
detoxification (Fig. 7D). However, two enzymes transcrip-
tionally regulated by NRF2, HO-1 (Fig. 7E, G, left panel),
and NQO1 (Fig. 7F, G, right panel), which in Axin1+ /+ livers
were expressed around the central vein, exhibited exacerbated
expression in the Axin1- /- livers, covering the entire hepatic
lobule or expanding toward the periportal zone. Overall, these
results demonstrate that the disruption of Axin1 results in up-
regulation of NRF2 and its target genes in vivo and that NRF2
participates in liver zonation of antioxidant metabolism.
Discussion
In this study, we report a completely unexplored link be-
tween the canonical WNT-3A signaling pathway and the
regulation of antioxidant metabolism by transcription factor
FIG. 5. Association of NRF2 and Axin1 and disruption by WNT-3A. (A) Mouse hepatocytes were submitted to
control- or WNT-3A-CM for 3 h, as indicated. Input panels show the amount of NRF2 and Axin1 in the protein lysates.
NRF2 was immunoprecipitated with anti-NRF2 antibody or G protein as a negative control and analyzed by immunoblot
with anti-NRF2 and anti-Axin1 antibodies. (B) HEK293T cells were co-transfected with NRF2DETGE-V5, or b-Catenin as
control, and myc-Axin1, HA-GSK-3bD9, and Flag-b-TrCP. After 24 h, cells were treated with control- or WNT-3A-CM in
combination with MG132 (40lM, 3 h). One-fifth of the whole-protein lysate was used to control for protein expression as
shown in the upper panels (Input). The rest was immunoprecipitated with anti-V5, anti-b-Catenin antibodies, or G protein as
a negative control and analyzed by immunoblot with anti-V5, anti-b-Catenin, anti-myc, anti-HA, and anti-Flag anti-
bodies (Pull down). Filled arrowheads point to HA-GSK-3D9 and Flag-b-TrCP. Empty arrowheads point to the heavy
chains of the anti-V5 and anti-b-Catenin antibodies. (C) Diagram showing the exon organization of mouse Axin1 according
to NP_001153070, and the myc-Axin1 chimeras used in pull-down assays with C-terminal deletions of Axin1. The numbers
below Axin1 correspond to the amino-acid positions in the boundaries between exons. (D) Diagram showing the EYFP-
NRF2 chimeras with N-terminal deletions, used to map the region of interaction with Axin1. The numbers below NRF2
correspond to the amino-acid positions in the boundaries between the Neh domains. (E, F) HEK293T cells were co-
transfected with b-Catenin (E) or NRF2DETGE-V5 (F) and wild-type myc-Axin1 (WT) or the indicated deletion mutants.
After 24 h, cells were treated with the proteasome inhibitor MG132 (40lM, 3 h). One-fifth of whole-protein lysate was used
to control for protein expression as shown in the two upper panels (input). The rest of the protein lysates were im-
munoprecipitated with anti-b-Catenin (E) or anti-V5 (F) and immunoblotted as indicated in the lower panels. (G) HEK293T
cells were co-transfected with myc-Axin1 and EYFP-NRF2 deletion mutants. After 24 h from transfection, cells were
treated with the proteasome inhibitor MG132 (40lM, 3 h). One-fifth of whole-protein lysate was used to control for protein
expression as shown in the two upper panels (Input). The rest of the protein lysates were immunoprecipitated with anti-V5
and immunoblotted as indicated in the lower panels. EYFP, enhanced yellow fluorescent protein. To see this illustration in
color, the reader is referred to the web version of this article at www.liebertpub.com/ars
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NRF2. Figure 8A describes the elements identified in this
new signaling pathway. The canonical WNT pathway has
been traditionally connected with development and mainte-
nance of differentiated cell phenotypes, including those of
hepatocytes. It is, therefore, very interesting that at least in
the liver it exerts a part of this function through the regula-
tion of NRF2. Indeed, while WNT signaling has been dem-
onstrated to regulate antioxidant metabolism through the
b-Catenin-dependent upregulation of some antioxidant genes
(13, 35), it is now clear that it also targets the NRF2 signature.
This is done in a b-Catenin-independent manner (Fig. 1),
further suggesting that these transcription factors, although
regulated by WNT, operate independently.
Most signaling pathways lead to production of reactive
oxygen species that might contribute to regulation of NRF2
by interfering with the redox sensor KEAP1. In the case of
WNT, a role for this redox modulation was reported through
the RAC1 GTPase-dependent activation of NADPH oxidase 1
(NOX1) (22). In addition, the Wilms tumor gene on X
chromosome (WTX) inhibits degradation of NRF2 through
competitive binding to KEAP1 (5). These observations in-
dicated the importance of determining whether WNT
was somehow modulating the KEAP1/NRF2 response. We
found that the WNT regulation of NRF2 was independent
of KEAP1, because (i) WNT-3A stabilized the KEAP1-
insensitive mutant NRF2DETGE-V5 and (ii) WNT-3A stabi-
lized endogenous NRF2 in MEFs from Keap1 - /- mice.
On the other hand, we found that Axin1 binding, GSK-3b
phosphorylation, and b-TrCP ubiquitination of NRF2 were
disrupted byWNT-3A and, therefore, established the basis to
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FIG. 6. Selective loss of Axin1 in the livers of floxed Axin1 - /- mice increased NRF2 signature. (A) Liver extracts
from Axin1 + /+ and Axin1 - / - were immunoblotted with the indicated antibodies. Each lane corresponds to liver extracts
prepared from different mice. (B) Densitometric quantification of protein levels from representative blots of (A). Values are
mean – SEM (n= 3). *p< 0.05, **p< 0.01, and ***p< 0.001 versus Axin1 + /+ mice according to a Student’s t-test. (C)
mRNA levels of Axin1, Axin2, Myc, CyclinD1, and Gs. Values are mean –SEM (n = 3). *p< 0.05 versus Axin1+ / + mice,
according to a Student’s t-test. (D) mRNA levels of Hmox1, Nqo1, Gclc, Gclm, Gpx1, Gsta2, Gstm3, and Me1 determined
by qRT-PCR and normalized by b-Actin. Values are mean – SEM (n = 3). *p < 0.05, **p < 0.01, and ***p < 0.001 versus
Axin1 + /+ mice according to a Student’s t-test.
FIG. 7. Alteration of Axin1/NRF2 disrupts liver zonation of antioxidant metabolism. Five-micrometer-thick paraffin
sections from the livers of Axin1 + / + and Axin1- / - mice were stained as indicated. CV, central vein; PV, portal vein. Scale
bars = 100 lm. (A) NRF2 staining in the perivenous region of a hepatic lobule. (B) Negative control for the anti-NRF2
antibody in a section of Nrf2 - / - mouse liver. (C) Percentage of NRF2-positive nuclei in the perivenous region of Axin1 + /+
and Axin1 - /- mice. The number of cells with NRF2 nuclear staining was counted in fields around the perivenous region.
The total number of cells per field was obtained by adding the NRF2 nuclear positive cells and cells with Harris’
hematoxylin nuclear staining. Values are mean – SEM (n = 6 fields per genotype). ***p < 0.001 versus Axin1+ / + mice,
according to a Student’s t-test. (D) Similar zonation of GS in Axin1 + /+ and Axin1- / - livers, as expected from (10). (E)
HO-1 staining. (F) NQO1 staining. Upper panels for (E, F); note the increase in HO-1 and NQO1 staining intensity in the
Axin1 - /- liver. Lower panels for (E, F); note that in Axin1 + / + liver, expression of HO-1 and NQO1 is localized mainly in
the hepatocytes closest to the CV, while in Axin1- / - liver expression of these markers is evident in hepatocytes located at a
further distance. (G) Densitometric estimation of respective HO-1 and NQO1 staining. Twenty five perivenous regions from
five mice were analyzed with a mask of 20· 20 lm as indicated in Materials and Methods. Values correspond to percentage
of specific staining (n = 25) broken down by distance to the CV –SEM. *p< 0.05, **p < 0.01 according to two-way ANOVA
with post hoc Bonferroni’s test. To see this illustration in color, the reader is referred to the web version of this article at
www.liebertpub.com/ars
‰
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study this novel mechanism of NRF2 regulation. We mapped
the region of interaction between NRF2 and Axin1 to the
exon 6 of Axin1. This is a critical scaffolding segment of
Axin1, termed the central region, that enables Axin1 to in-
teract with several proteins, including transcription factors
b-Catenin, MYC, Smad3, and p53 as well as protein kinases
GSK-3b, CK1, MKK1, and MKK4, among others (36). This
region is natively unfolded, and it has been suggested to
undergo a sort of ‘‘induced fit’’ to accommodate specific
groups of proteins. Thus, our study suggests that Axin1
scaffolds a complex with NRF2, GSK-3b, and b-TrCP to
downregulate NRF2. The existence of several proteins
which compete for binding to Axin1 in the same region
suggests that Axin1 levels may be limiting to control specific
WNT pathways.
In addition to the well-characterized KEAP1/NRF2 sys-
tem, it is becoming clear that other regulatory mechanisms
also operate on NRF2. In fact, graded reduction in expression
of Keap1, achieved in mouse liver by several genetic tech-
niques, leads to graded increase NRF2 levels (47, 55), sug-
gesting that KEAP1 operates close to saturation and that an
increase in NRF2 overloads this mechanism. Formal proof
of this hypothesis is lacking, as, to our knowledge, a com-
parison of turnovers of KEAP1 and NRF2 under different
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experimental conditions has not yet been reported. In any
case, the modest induction of NRF2 that escapes KEAP1
regulation has a physiological meaning. As an example, in
pancreatic cancer, a modest K-Ras-dependent upregulation
of less than two-fold in NRF2 transcription causes an increase
in the NRF2 signature (9). Here, we extend the importance of
modest increases in NRF2 to the modulation of antioxidant
metabolism in the liver, and we propose that NRF2 levels
appear to be fine-tuned not only by the relative levels of
KEAP1 but also by other NRF2 interacting proteins which
now include Axin1.
Themolecular mechanisms responsible for maintenance of
metabolic zonation in the liver are poorly understood. Oxy-
gen gradients and hormones that run across the liver lobule
participate in acquisition of periportal versus perivenous
phenotypes of hepatocytes, and at least b-Catenin has been
also involved in the upregulation of some antioxidant en-
zymes (2). The implication of NRF2 has not yet been studied,
but very recently, it has been reported that Nrf2 - /- mice
develop a congenital intrahepatic shunt which alters hepatic
oxygen and protein expression gradients (44). Here, by
making use of liver-specific floxed Axin1 - / - mice, we found
a substantial increase in the transcriptional activity of NRF2
as determined by increased protein and mRNA levels of
HO-1, NQO1, GCLM, ME1, and G6PDH. Moreover, com-
pared with control livers, NRF2, HO-1, and NQO1 expres-
sion expanded to hepatocytes located beyond the initial rows
of the hepatic central vein. In summary, these results indicate
that WNT signaling to NRF2 participates in maintenance of
the perivenous hepatocyte phenotype. Figure 8B proposes
a mechanism used by WNT/Axin1 to control zonation of
NRF2 signature in the liver. It is interesting that other WNT-
regulated transcription factors do not have this effect. Thus,
c-MYC, a crucial element in APC-related tumorigenesis,
does not seem to participate in liver zonation of ammonia
detoxification (4). These facts suggest that Axin1 scaffolds
several protein complexes with different functions.
It may seem somewhat intriguing that NRF2-mediated
antioxidant metabolism is more noticeable in the perivenous
zone, rather than in the periportal zone, which is more ex-
posed to delivery of oxygen from the hepatic artery and
xenobiotics from the portal vein. A possible explanation to
this paradox is again the distinction between KEAP1-
dependent regulation of NRF2, adapting NRF2 levels to
transient demands, which should impact the periportal re-
gion, and the effect of WNT signaling that may be more
related to the basal physiology of topologically different
hepatocytes. There is evidence of basal low oxygen tension
in the perivenous zone, with increased expression of
hypoxia-inducible factor-1a, 2a, and 3a (23). Considering
that hypoxia may lead to release of mitochondria-generated
reactive oxygen species, a WNT-regulated developmental
control of NRF2 might provide a KEAP1-independent layer
of regulation to this zone.
The finding of an Axin1/NRF2 complex and its rele-
vance in liver metabolism has important consequences for
FIG. 8. Proposed modulation of
NRF2 by WNT-3A. (A) Under un-
stimulated conditions (WNT OFF),
Axin1 scaffolds NRF2 and GSK-3,
facilitating NRF2 phosphorylation and
further b-TrCP-dependent ubiquitina-
tion and proteasomal degradation.
Under WNT-3A stimulation (WNT
ON), Axin1 is recruited to the mem-
brane, along with receptors LRP5/6
and Frizzled, and NRF2 is no longer
phosphorylated by GSK-3. Then,
NRF2 escapes b-TrCP-induced deg-
radation, enters the nucleus, and di-
merizes with MAF protein family
members to transactivate ARE-
containing genes, including, for ex-
ample, those coding HO-1, NQO1,
ME1, and G6PD. (B) Schematic in-
terpretation of how WNT/Axin1
modulates zonation of the NRF2 sig-
nature. The concentration gradient of
canonical WNT factors decreases
from the perivenous to the periportal
zones (49). Therefore, in normal liv-
ers, WNT signaling promotes NRF2
transcriptional activity to the first he-
patocyte rows next to the CV. By
contrast, Axin1 deficiency enhances
NRF2 signature along the entire he-
patic lobule. ME1, malic enzyme 1.
To see this illustration in color, the
reader is referred to the web version of
this article at www.liebertpub.com/ars
566 RADA ET AL.
therapy of liver diseases and probably others. Several phar-
macological pipelines are being developed to inhibit WNT,
particularly in cancer therapy (37). These drugs should be
now tested for add-on effect on NRF2. On the other hand,
WNT activators are also being considered and these should
also provide a KEAP1-independent or complementary
mechanism of NRF2 activation Here, we have used Axin1
stabilizers, acting as Tankyrase inhibitors (28), to inhibit
NRF2 induction by WNT. Together, these studies open new
therapeutic possibilities by targeting WNT/b-Catenin and, in
our case, WNT/NRF2.
Materials and Methods
Cell culture and reagents
Hepatocytes from neonatal mice were obtained as pre-
viously reported (14) and grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum, 2mM L-glutamine, 20 mM HEPES, and
80 lg/ml gentamycin. HEK293T cells were grown in DMEM
supplemented with 10% fetal bovine serum and 80 lg/ml
gentamycin. MEFs from Keap1 - /- mice and Keap1 + /+ lit-
termates were kindly provided by Dr. Ken Itoh (Center for
Advanced Medical Research, Hirosaki University Graduate
School of Medicine, Japan). Conditioned media from L-
Control (Control-CM) and L-WNT-3A (WNT-3A-CM)
confluent cells (grown in DMEM supplemented with 10%
fetal bovine serum, 0.5U/ml penicillin, and 0.5 lg/ml strep-
tomycin) was collected and passed through a 0.2 lm filter.
Transient transfections were performed with calcium phos-
phate, using reagents from Sigma-Aldrich, or with Trans-
Fectin lipid reagent from Bio-Rad. MG132, XAV939, and
IWR-1 were from Sigma-Aldrich. Recombinant WNT-3A
was from Cell Guidance Systems.
Conditional Axin1 mutant mice
All animal experiments were performed according to UK
Home Office regulations. Details of the generation of
Axin1 - /- mice are described in (10). Briefly, Ah-Cre mice
were intercrossed with mice carrying LoxP-flanked Axin1
(Axin1fl/fl) and Rosa 26 LacZ reporter alleles (LacZ) to gen-
erate Axin1 - /- mice. Cre activity was induced by four in-
traperitoneal injections of b-naphthoflavone (BNF; 80mg/kg
body wt) over 4 days. Littermates were used as controls
(Axin1 + /+ ). Three months after injections of BNF, the ani-
mals were sacrificed and liver samples were snap frozen in
liquid nitrogen and stored at - 80C. For immunoblots, livers
were homogenized in lysis buffer (50mM HEPES, 1%
Triton X-100, 10mM EDTA, 50mM sodium pyrophosphate,
1mM phenylmethylsulfonyl fluoride, 0.1M sodium fluoride,
10mM sodium orthovanadate, and 1 lg/ml leupeptin) using
the Brinkman PT 10/35 Polytron (American Laboratory
Trading, Inc.). Extracts were kept ice cold at all times. Liver
extracts were cleared by microcentrifugation at 40,000 g
(40min, 4C). The supernatants were aliquoted and stored at
- 80C. For mRNA, livers were homogenized in TRIzol re-
agent using the Brinkman PT 10/35 Polytron.
Plasmids
Expression vectors pcDNA3.1-mNRF2-V5/HisB and
pcDNA3.1-mNRF2DETGE-V5/HisB were provided by Dr.
John D. Hayes (Biomedical Research Institute, Ninewells
Hospital and Medical School, University of Dundee). pCGN-
HA-GSK-3bD9 was provided by Dr. Akira Kikuchi (De-
partment of Biochemistry, Faculty of Medicine, Hiroshima
University). pcDNA3-Flag-b-TrCP2 was provided by
Dr. Tomoki Chiba (Department of Molecular Biology,
University of Tsukuba). Plasmid encoding b-TrCPDFbox
(pcDNA3-b-TrCPDFbox-HA) was provided by Dr. Serge Y.
Fuchs (Department of Animal Biology, University of
Pennsylvania, Philadelphia, PA). Chimeric deletion con-
structs of the pEYFP-mNRF2-V5 were generated as de-
scribed in (39, 40). pcDNA3.1-mNRF2DETGE 6S/6A-V5/HisB
was previously described in (38). Expression vector for
WNT-3A (pCCBS-Hygro-WNT-3A-HA) was provided by
Dr. Stuart A. Aaronson (Department of Oncological Sci-
ences, Mount Sinai School of Medicine, New York, NY).
Plasmid encoding mouse myc-Axin1 (pCMV5-myc-Axin1)
was kindly provided by Dr. Sheng-Cai Lin (Department of
Biochemistry, Hong Kong University of Science and Tech-
nology, Clear Water Bay, Kowloon, Hong Kong, China).
Expression vectors for the myc-Axin1 deletion mutants were
generated by polymerase chain reaction (PCR) using
pCMV5-myc-Axin1 as a template with the following prim-
ers: Common forward, 5¢ TAACGCGGCCGCAAGGT
GGAAAAGGTGGACTGA 3¢, reverse for myc-Axin1 (ex-
ons 2–5), 5¢ TAACGCGGCCGCCCATGCGTACACGCTT
CAGCC 3¢, reverse for myc-Axin1 (2–6), 5¢ TAACGCGG
CCGCCACCAAAGGCCAAATCCCCAGC 3¢, reverse for
myc-Axin1 (2–7), 5¢ TAACGCGGCCGCTCCCATGGCCT
GCCTTCCGGTG 3¢ and reverse for myc-Axin1 (2–8), 5¢
TAACGCGGCCGCTCCTCTGCTTGGAGGGCAGTTT 3¢
(NotI sites are underlined).
Analysis of mRNA levels
TotalRNAextraction, reverse transcription, andquantitative
PCR were done as detailed in (39). See Supplementary Table
S1 for primer sequences. Data analysis is based on the DDCt
method with normalization of the raw data to housekeeping
genes as described in the manufacturer’s manual (Applied
Biosystems). All PCRs were performed at least in triplicate.
Immunoblotting
Immunoblots were performed as in (39). The primary
antibodies are described in Supplementary Table S2. Pro-
teins were detected by enhanced chemiluminescence (GE
Healthcare).
siRNA assays
siRNA used to knock downmouse NRF2, mouse b-TrCP1,
mouse b-TrCP2, human GSK-3a, human GSK3b and mouse
Axin1 expression, and control scrambled siRNA sequence
are described in Supplementary Table S3. Immortalized he-
patocytes were seeded in six-well plates (50,000 cells/well in
2ml medium). When 40%–50% confluence was reached,
cells were transfected with 25nM siRNAs following Dharma-
FECT General Transfection Protocol (Dharmacon). After
48 h, cells were used for experiments. HEK293T cells were
seeded in six-well plates (200,000 cells/well in 2ml medium)
before being transfected using calcium phosphate and the
appropriate NRF2 expression plasmids. To knock down
GSK-3 isoforms, we performed siRNA transfection during
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two consecutive days. On the first day, we knocked down
GSK-3 using 80 ng of Silencer Select validated siRNA with
30 ll of siPORT reagent, and on the second day we used
40 ng of Silencer Select validated siRNA with 15ll of
siPORT reagent. Twenty four hours later, the cells were col-
lected and NRF2 and GSK-3 levels were analyzed.Keap1 - / -
MEFs were seeded in six-well plates (200,000 cells/well in
2ml medium) at 16 h before transfection. To knock down
Axin1, we performed siRNA transfection during two con-
secutive days. On the first day, we knocked down Axin1
using 50 or 100 pmol of Silencer Select validated siRNAwith
20 ll of RNAimax Lipofectamine (Life Technologies), and
on the second day we used 50 or 100 pmol of Silencer Select
validated siRNA with 20 ll of RNAimax Lipofectamine.
Twenty four hours later, the cells were harvested for analysis.
Luciferase assays
Transient transfections of HEK293T or Keap1- / - cells
were performed with the expression vectors ARE-LUC (a gift
of Dr J. Alam, Department of Molecular Genetics, Ochsner
Clinic Foundation, USA), or TOPFlash and FOPFlash, as
indicated. pTK-Renilla were used as an internal control
vector (Promega). Luciferase assays were performed as de-
scribed in (39).
In vivo ubiquitination assay
This was carried out using the method of Treier et al. (50).
HEK293T cells were transfected with His-tagged Ubiquitin
along with the indicated plasmids. Sixteen hours later, the
transfected cells were washed with prewarmed phosphate-
buffered saline and scraped into 0.4ml of phosphate-buffered
saline. Whole-cell lysates were prepared from 80ll of the
cell suspension and are referred to as the ‘‘input’’ fraction.
His-tagged protein was purified from the remainder of the
cell suspension as follows: The cell suspension was lysed by
the addition to 1ml of buffer A (6 M guanidine:HCl, 10mM
Tris in 0.1 M phosphate buffer, pH 8.0) supplemented with
5mM imidazole. The resulting lysate was sonicated, to re-
duce viscosity. Then, 60 ll of Probond resin (Invitrogen)
was added, and the mixture was rotated for 4 h at 25C.
Thereafter, the beads were washed sequentially with buffer A
supplemented with 0.1% (v/v) Triton X-100, buffer B (8 M
urea, 10mM Tris in 0.1 M phosphate buffer, pH 8.0) sup-
plemented with 0.1% Triton X-100, buffer C (8 M urea,
10mM Tris in 0.1M phosphate buffer, pH 6.5) supplemented
with 0.2% Triton X-100, and finally, buffer C supplemented
with 0.1% Triton X-100. Bound material was eluted from the
beads by suspension in 50 ll of modified Laemmli sample
buffer (20mM Tris-Cl, pH 6.8, 10% [v/v] glycerol, 0.8%
[w/v] SDS, 0.1% [w/v] bromophenol blue, 0.72 M 2-
mercaptoethanol and 300mM imidazole) followed by boil-
ing for 4min. The suspension was centrifuged (16,000 g,
1min, 20C), and the resulting supernatant was collected and
is referred to as the ‘‘pull down’’ fraction.
Immunohistochemistry
Liver tissues from Axin1+ / + and Axin1- /- mice were al-
ways dissected from the same part of the liver and fixed in
ice-cold 10% neutral buffered formalin for no longer than
24 h before being processed into paraffin wax according to
standard procedures. Tissue sections (5lm thick) were used.
The Streptavidin Biotin Peroxidase method was performed
as follows: Sections were mounted on slides coated with
3-aminopropyltriethoxy-silane (Sigma Chemical Co.), hy-
drated after deparaffinization, and incubated for 10min in
0.3% H2O2 in phosphate-buffered saline (PBS) to reduce
endogenous peroxidase activity. For antigen retrieval, sec-
tions were submitted twice to microwave pretreatment for
2.5min at 800W in sodium citrate buffer 0.01 M (pH 6) and
subsequently blocked with Tris-buffered saline containing
1% bovine serum albumin. All sections were incubated for
16–20 h at 4C with the primary antibody (diluted in PBS
containing 1% serum albumin). Sections were washed in PBS
to remove unbound primary antibodies and then incubated
with a broad spectrum second antibody solution at room
temperature. After incubations, the sections were washed and
submitted to the supersensitive Streptavidin Biotin Perox-
idase (Histostain-SP IHC kit, DAB sprectum, 95-9643; Life
Technologies). The immunoreaction was developed by in-
cubation with 3, 3-diaminobenzidine (DAB; Sigma-Aldrich)
with H2O2 and diluted in phosphate buffer for peroxidase
kits. The sections were counterstained with Harris’ hema-
toxylin, dehydrated in ethanol, and mounted in DePex
(Thermo Fisher Scientific). The primary antibodies and op-
timal dilutions used for these studies were as follows: anti-
mouse NRF2 (1:50; generated in Cuadrado’s laboratory),
anti-GS (1:1000; Sigma-Aldrich), anti-HO-1 (1:50;Millipore),
and anti-NQO1 (1:50; Abcam).
Subcellular fractionation
Keap1 + /+ and Keap1 - /- MEFs were seeded in p100
plates (2· 106 cells per plate). Cells were treated with Con-
trol or WNT-3A-CM for 4 h. Cytosolic and nuclear fractions
were prepared as previously described (12). The supernatants
from cytosolic and nuclear fractions were resolved in SDS-
PAGE and immunoblotted with the indicated antibodies.
Co-immunoprecipitation
Assays were performed as indicated in (39). The samples
were resolved by SDS-PAGE and immunoblotted. Mouse
IgG TrueBlot (eBiosciences) was used as peroxidase-
conjugated secondary antibody (1:10,000 dilution) to avoid
interference with the 55 kDa heavy and 23 kDa light chains of
the immunoprecipitating antibody.
Image analyses and statistics
Different band intensities (arbitrary units) corresponding
to immunoblot detection of protein samples were quantified
using the MCID software (MCID). Student’s t-test, one-way,
and two-way analysis of variance were used to assess dif-
ferences between groups. Unless indicated, all experiments
were performed at least thrice with similar results. The values
in the graphs correspond to the mean of at least three samples.
Results are expressed as mean– SEM.
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Abbreviations Used
b-TrCP¼ beta-transducin repeat containing
protein
ANOVA¼ analysis of variance
ARE¼ antioxidant response element
DMEM¼Dulbecco’s modified Eagle’s medium
EYFP¼ enhanced yellow fluorescent protein
G6PDH¼ glucose 6 phosphate dehydrogenase
Gclc¼ c-glutamyl cysteine ligase catalytic
subunit
Gclm¼ c-glutamyl cysteine ligase modulator
subunit
CM¼ conditioned medium
Gpx1¼ glutathione peroxidase 1
ME1¼malic enzyme 1
Nqo1¼NAD(P)H:quinone oxidoreductase 1
GS¼ glutamine synthetase
GSK-3¼ glycogen synthase kinase-3
HEK293T¼ human embryonic kidney cells
expressing the T antigen
Hmox1¼ gene encoding heme oxigenase-1
HO-1¼ heme oxygenase-1
IHC¼ immunohistochemistry
KEAP1¼Kelch-like ECH-associated protein 1
Me1¼malic enzyme
MEFs¼mouse embryonic fibroblasts
NFE2L2¼ nuclear factor
(erythroid-derived 2)-like 2
NOX1¼NADPH oxidase 1
NRF2¼ nuclear factor
(erythroid-derived 2)-like 2
PCR¼ polymerase chain reaction
PTEN¼ phosphatase and tensin homolog
qRT-PCR¼ quantitative real time PCR
Rbx1¼ ring-box 1
SCF¼ Skp, Cullin, and F-box containing
complex
siRNA¼ short interfering RNA
TCF/LEF¼T-cell factor/lymphoid enhancer factor
WB¼Western blot
WNT¼wingless-type protein
WTX¼Wilms tumor gene on X chromosome
A WNT-3A/NRF2 AXIS REGULATES ANTIOXIDANT METABOLISM 571
